✦ LIBER ✦

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I

✍ Scribed by Afsar Ali Mian, Anna Metodieva, Susanne Badura, Mamduh Khateb, Nili Ruimi, Yousef Najajreh, Oliver Gerhard Ottmann, Jamal Mahajna, Martin Ruthardt

Book ID: 119897455
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 389 KB
Volume: 12
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-12-411

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

794: Crizotinib is an allosteric ABL-inh

794: Crizotinib is an allosteric ABL-inhibitor targeting both native BCR/ABL and BCR/ABL-T315I in vitro and in vivo models of PH+ leukemia

✍ Mahajna, J.; Khamaisie, H.; Ruimi, N.; Agbarya, A.; Eshel, E.; Dally, N.; Ottman 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Oligomerization inhibition, combined wit

Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL

✍ Mian, A A; Oancea, C; Zhao, Z; Ottmann, O G; Ruthardt, M 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 377 KB

Mechanisms of resistance to BCR-ABL and

Mechanisms of resistance to BCR-ABL and other kinase inhibitors

✍ Lamontanara, Allan Joaquim; Gencer, Emel Basak; Kuzyk, Orest; Hantschel, Oliver 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 523 KB

Dynamic change of T315I BCR-ABL kinase d

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors

✍ Wan-Seok Kim; Dongho Kim; Dong-Wook Kim; Il-Young Kweon; Soo-Hyun Kim; Hyun-Gyun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 1 views

## Abstract We analysed the dynamic change of imatinib‐resistant mutations in BCR‐ABL kinase domain focusing on T315I mutation during dasatinib or nilotinib therapy. Fifty‐five imatinib‐resistant chronic myeloid leukaemia patients (32 patients with imatinib‐resistant mutations and 23 patients witho

The Growing Arsenal of ATP-Competitive a

The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR-ABL

✍ Hantschel, O.; Grebien, F.; Superti-Furga, G. 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 446 KB

Target spectrum of the BCR-ABL inhibitor

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

✍ Hantschel, Oliver; Rix, Uwe; Superti-Furga, Giulio 📂 Article 📅 2008 🏛 Informa plc 🌐 English ⚖ 441 KB